Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All bamlanivimab/etesevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 40% Improvement Relative Risk Hospitalization/ER 62% Bamlanivimab/e..  Karr et al.  EARLY TREATMENT Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective 46 patients in the USA (December 2020 - January 2021) Lower hospitalization (p=0.52) and fewer hosp./ER visits (p=0.22), not sig. c19early.org Karr et al., Military Medicine, May 2021 Favors bamlanivimab/e.. Favors control

Bamlanivimab Use in a Military Treatment Facility

Karr et al., Military Medicine, doi:10.1093/milmed/usab188
May 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
20th treatment shown to reduce risk in May 2021
 
*, now known with p = 0.00039 from 19 studies, recognized in 4 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 40 outpatients showing improvement in symptoms and lower risk of hospitalization/ER visits with bamlanivimab, without statistical significance.
Different counts for hospitalization are provided in the abstract and text: "Three of 40 (7.5%) patients in the treatment group required inpatient admission" and "In the treatment group, 4 of 40 (10%) patients were hospitalized after infusion."
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron Haars, Liu, Pochtovyi, Sheward, VanBlargan.
Although the 40% lower hospitalization is not statistically significant, it is consistent with the significant 41% lower hospitalization [27‑52%] from meta analysis of the 13 hospitalization results to date.
risk of hospitalization, 40.0% lower, RR 0.60, p = 0.52, treatment 4 of 40 (10.0%), control 1 of 6 (16.7%), NNT 15, day 30.
risk of hospitalization/ER, 62.5% lower, RR 0.38, p = 0.22, treatment 5 of 40 (12.5%), control 2 of 6 (33.3%), NNT 4.8, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Karr et al., 16 May 2021, retrospective, USA, peer-reviewed, 5 authors, study period 3 December, 2020 - 12 January, 2021.
This PaperBamlaniv../e..All
Bamlanivimab Use in a Military Treatment Facility
USAF, MC Eric Karr, USAF, MC Theodore Chung, USAF, MC Kathryn Burtson, PhD Ronald Markert, USAF, MC Devin Kelly
Military Medicine, doi:10.1093/milmed/usab188
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), was first identified in 2019 in Wuhan, China, and has rapidly spread across the world. As of April 2021, SARS-CoV-2 has infected more than 140,000,000 and caused more than 3,000,000 deaths globally. In November 2020, the monoclonal antibody bamlanivimab was approved by the FDA for non-hospitalized patients with SARS-CoV-2 (COVID-19) who possessed risk factors for progression to severe COVID-19. This provided a treatment option that may help prevent hospitalization. Methods: Patients who regularly received ambulatory care at a military treatment facility and who were diagnosed with mildto-moderate COVID-19 and possessed risk factors for progression to severe COVID-19 were treated with a single, intravenous infusion (700 mg) of the virus-neutralizing monoclonal antibody bamlanivimab. The primary outcome was improvement of self-reported symptoms within 24 to 72 hours of receiving the infusion. The secondary outcome was prevention of disease progression requiring emergency department (ED) utilization or hospitalization related to COVID-19 within 30 days of infusion. Bamlanivimab was administered in accordance with the FDA's approval and Defense Health Agency's guidance, including follow-up within 72 hours of administration. Institutional Review Board (IRB) approval was obtained. Results: Of the COVID-19 patients who were given the option of a bamlanivimab infusion, 40 accepted and 6 did not (40/46, 86.9%). Thirty-six of 40 patients in the treatment group were contacted within 72 hours. ED/hospitalization information was available for all 46 patients. In the treatment group, 94.4% (34/36) reported global improvement. Three of 40 (7.5%) patients in the treatment group required inpatient admission, and 2 of 40 patients (5%) required ED evaluation within 30 days of infusion. Therefore, 5 of 40 (12.5%) patients required evaluation shortly after infusion, while 2 of 6 (33.3%) patients who declined treatment required hospital evaluation or admission related to COVID-19 within 30 days of infusion (P = .15). Conclusions: Global improvement of symptoms within 24 to 72 hours of infusion was reported by 94.4% of patients receiving bamlanivimab; however, statistical significance could not be determined due to the small sample size and lack of placebo group due to study design. Furthermore, ED visits and hospital admissions were analyzed, but with only six patients in the comparison group, the relative risk was not statistically significant and could not be precisely estimated. In the future, this study can be replicated with both larger control/treatment arms to validate the initial results of this small, retrospective, cohort study.
CONFLICT OF INTEREST STATEMENT None declared.
References
Baum, Ajithdoss, Copin, REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters, Science
Bhimraj, Morgan, Shumaker, Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19, Clin Infect Dis
Chan, Yuan, Kok, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster, Lancet
Cummings, Baldwin, Abrams, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet
Farooqi, Dhawan, Morgan, Dinh, Nedd et al., Treatment of severe COVID-19 with tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: a case report and literature review, Trop Med Infect Dis
Goldman, Lye, Hui, Remdesivir for 5 or 10 days in patients with severe Covid-19, N Engl J Med
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Jehi, Ji, Milinovich, Development and validation of a model for individualized prediction of hospitalization risk in 4,536 patients with COVID-19, PLoS One
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA
Liu, Yan, Wan, Viral dynamics in mild and severe cases of COVID-19, Lancet Infect Dis
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit